Abstract:3067 Background: Early cancer detection is key to reducing cancer deaths. Unfortunately, many established cancer screening technologies are not suitable for use in low- and middle-income countries due to expenses, complexity, and dependency on extensive medical infrastructure. Therefore, a simple, affordable, efficient multi-cancer early detection test is a major unmet need. Methods: This study enrolled nearly 10,000 participants (1959 cancer cases and 7423 non-cancer cases) containing more than nine common cancer types. One tube of peripheral blood samples was collected from each participant and quantified a panel of seven selected protein tumor markers (PTMs) by a clinical common electrochemiluminescence immunoassay analyzer. A protein assay named OncoSeek was established using artificial intelligence to distinguish cancer from non-cancer cases by calculating the probability of cancer (POC) index based on the quantification results of 7 PTMs and clinical information including gender and age of the subjects. Then using another model to predict the possible affected tissue of origin (TOO) who has been detected with cancer signal. Results: In this study, we found that the conventional clinical method relied only on a single threshold for each protein tumor marker which would make a big problem that was when combining the result of those markers, the false positive rate would accumulate as the number of tests increased. Nevertheless, OncoSeek was empowered by artificial intelligence technology to significantly reduce the false positive rate, increasing the specificity from 56.9% (95% confidence interval (CI): 55.8% to 58.0%) to 92.9% (95% CI: 92.3% to 93.5%). In all cancer types sensitivity of the OncoSeek test was 51.7% (95% CI: 49.4% to 53.9%). The sensitivities ranged from 37.1% to 77.6% for the detection of the nine common cancer types (breast, colorectum, esophagus, liver, lung, lymphoma, ovary, pancreas, stomach), which account for ~59.2% of global cancer deaths annually. Furthermore, it has shown excellent sensitivity in several high-mortality cancer types for which there are a lack of routine screening tests in the clinic, such as the sensitivity of pancreatic cancer was 77.6% (95% CI: 69.3% to 84.6%). The overall accuracy of tissue of origin (TOO) prediction in true positives was 66.8%, which reduced the clinical diagnostic workup. Conclusions: In summary, this study supported that OncoSeek significantly outperforms the conventional clinical method, representing a novel blood-based test for multi-cancer early detection which is a non-invasive, easier, and efficient approach. Moreover, the accuracy of TOO of it which facilitates the follow-up diagnostic workup. As well as this method is affordable (the cost of the test is less than $25) and requires nothing more than a blood draw at the screening sites, which makes it more practical in low- and middle-income countries.

Low-cost Thermophoretic Profiling of Extracellular-Vesicle Surface Proteins for the Early Detection and Classification of Cancers

Accurate Cancer Diagnosis and Stage Monitoring Enabled by Comprehensive Profiling of Different Types of Exosomal Biomarkers: Surface Proteins and Mirnas

Effective Enrichment of Trace Exosomes for the Label-Free SERS Detection Via Low-Cost Thermophoretic Profiling.

Facile fluorescent aptasensor using aggregation-induced emission luminogens for exosomal proteins profiling towards liquid biopsy

Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test

Enabling Sensitive Phenotypic Profiling of Cancer-Derived Small Extracellular Vesicles Using Surface-Enhanced Raman Spectroscopy Nanotags

An aptamer‐guided fluorescence polarisation platform for extracellular vesicle liquid biopsy

Accurate and Convenient Lung Cancer Diagnosis Through Detection of Extracellular Vesicle Membrane Proteins Via Förster Resonance Energy Transfer.

Colocalization of Cancer-Associated Biomarkers on Single Extracellular Vesicles for Early Detection of Cancer

Profiling extracellular vesicle surface proteins with 10 µL peripheral plasma within 4 h

Early Cancer Detection by Serum Biomolecular Fingerprinting Spectroscopy with Machine Learning

Simultaneous detection of membrane protein and mRNA at single extracellular vesicle level by droplet microfluidics for cancer diagnosis

A panel of seven protein tumor markers for multi-cancer early detection by artificial intelligence.

CRISPR-based dual-aptamer proximity ligation coupled hybridization chain reaction for precise detection of tumor extracellular vesicles and cancer diagnosis

Profiling Extracellular Vesicle Surface Proteins with 10 Μl Peripheral Plasma Within 4 H.

CancerScreen: A Novel Ultrasensitive Liquid Biopsy for Early-Stage Cancer Detection by Ctdna Duplex Sequencing and Tissue of Origin Identification with Supervised Machine Learning.

Molecular Detection and Analysis of Exosomes Using Surface-Enhanced Raman Scattering Gold Nanorods and a Miniaturized Device

Exosomal Surface Protein Detection with Quantum Dots and Immunomagnetic Capture for Cancer Detection

An Ultrasensitive Strand Displacement Signal Amplification-Assisted Synchronous Fluorescence Assay for Surface Proteins of Small Extracellular Vesicle Analysis and Cancer Identification

A Novel Blood Plasma Analysis Technique Combining Membrane Electrophoresis with Silver Nanoparticle-Based SERS Spectroscopy for Potential Applications in Noninvasive Cancer Detection

Microfluidic-based exosome isolation and highly sensitive aptamer exosome membrane protein detection for lung cancer diagnosis